HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch + Lomb Turns To Familiar Face As CEO, Brent Saunders

Executive Summary

Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.

You may also be interested in...



Bausch + Lomb Patiently 'Semi-Private' While Bausch Health Plots Path To Spin-Out Completion

B+L using period of Bausch Health’s near-full ownership to plan for future. "When the spin comes, then we can spend a lot more time with our investors. But right now, I just have to take the elevator down two floors and I can see the 90% shareholder,” says CEO Brent Saunders.

US Q2 Consumer Health Earnings Preview: Two Firsts On Table For Perrigo, One For Kenvue

Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.

With ‘Roadmap To Accelerate Growth,’ Saunders Quick Out Of Gate In Return To Bausch + Lomb

“Multi-year plan with three phases, all with measurable, clear objectives” starts with “rewire company for optimal performance” before moving to “innovate and execute” and then to “accelerate growth,” CEO says.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel